News | November 12, 2025
JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Annual EBITDA margin expands by 170 basis points
For the full year FY25, net profit soared 12x to Rs 345 crore
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Q3 FY25 revenue up 24% to Rs 3,230 crore
Acquisition expands high-value medical platform
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Subscribe To Our Newsletter & Stay Updated
